Feb 14, 2023 1:50 pm EST LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
Feb 7, 2023 12:16 pm EST LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS
Nov 30, 2022 8:05 am EST LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference
Oct 13, 2022 8:30 am EDT LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
Jun 21, 2022 8:30 am EDT LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS
Jun 15, 2022 8:30 am EDT LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS
Apr 14, 2022 6:45 pm EDT LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market
Apr 12, 2022 1:52 pm EDT LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
Apr 12, 2022 8:30 am EDT LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations
Mar 22, 2022 8:30 am EDT Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy
